Diseases & Conditions
Grants & Contracts
News & Events
NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.
The ACTG NL consists of Core Laboratory groups in immunology, pharmacology, virology and TB.
The Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) program supports the evaluation of early-stage diagnostics and novel diagnostic strategies for TB, in TB endemic countries to address an urgent need for improved tuberculosis (TB) diagnostics.
This service can be used to develop and perform a variety of analytical assays to assess the properties of drug substances and their formulations.
This service program supports the development and manufacture, of a wide variety of pharmaceutical dosage formulations, including tablets, capsules, semi-solid preparations, injectibles, and sustained-release products. If requested, manufacturing can be done under GMP.
This service provides chemical synthesis of lead compounds for use in additional drug development studies. Compounds must previously have been successfully synthesized to be candidates for this service. Synthesis of new analogs is not supported.
The Microbicide Trials Network (MTN) is a NIAID-funded worldwide collaborative clinical trials network focused on preventing the sexual transmission of HIV. The MTN accepts concepts for new protocols, ancillary study proposals, secondary data analysis requests, and dataset requests.
The National Institutes of Health (NIH) HIV Reagent Program provides critical research reagents and resources to the scientific community.
The Phase I Clinical Trial Units for Therapeutics support the design, development, implementation, and conduct of Phase I clinical trials to assess safety, pharmacokinetics, and/or pharmacodynamics of licensed and investigational therapeutic products, including immunomodulatory agents and monoclo
Current methods for monitoring HIV-infected patients on antiretroviral therapy are expensive and technologically complex, making it difficult for use in resource-limited countries around the world.